Rheum for Everyone, Episode 24 (video)| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Guidelines for ILD in Systemic Autoimmune Rheumatic Disease

Ruth Jessen Hickman, MD  |  August 26, 2025

Figure 3. Click to enlarge.

Glucocorticoids

Recommendations: A strong recommendation against glucocorticoid use in patients with SSc as first-line treatment of SARD-ILD was made. However, for patients with ILD related to other SARDs, the conditional recommendation is in favor of glucocorticoid treatment in conjunction with another therapy, usually a traditional immunosuppressive.

The strong recommendation against glucocorticoids as first-line ILD treatment in systemic sclerosis, one of the few strong recommendations in the guideline, is due to the risk of inducing renal crisis in this population. “I think rheumatologists are very familiar with this risk, but people outside the rheumatology community [may] be less so,” says Dr. Bernstein.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In all likelihood, notes Dr. Johnson, clinicians should also avoid glucocorticoids in patients with mixed connective tissue disease who have a scleroderma-dominant phenotype.

SJÖGREN’S DISEASE-SPECIFIC RECOMMENDATIONS

For first-line therapy in patients with Sjögren’s disease-associated ILD, the guideline recommends mycophenolate, azathioprine and rituximab, with cyclophosphamide as an option. Glucorticoids are recommended in the short term (for three months or less).

The authors state that rituximab may be preferred in the setting of Sjögren’s neuropathy, inflammatory arthritis or myositis because of its potential effectiveness for treating these manifestations.
The guideline conditionally recommends against nintedanib as a first-line ILD treatment option for patients with Sjögren’s disease-associated ILD.
If the ILD persists, consider switching to an alternative first-line therapy. The authors state that referral for lung transplant should be considered at an appropriate time for persistent Sjögren’s disease-associated ILD.
There are conditional recommendations against continuing glucocorticoids in the long term, as well as against using tocilizumab as a treatment option.

Immunomodulators: Initial Treatment

Recommendations: Mycophenolate, rituximab, cyclophosphamide and azathioprine are conditionally recommended as first-line treatments for SARD-ILD, with mycophenolate conditionally recommended above these other agents.

Dr. Johnson notes that guideline developers preferred some agents due to published literature and expert experience, but other agents may be options in specific circumstances. Thus, although these are all potential first-line options, cyclophosphamide and azathioprine may be considered additional options rather than preferred first-line treatment.


Ruth Jessen Hickman, MD, photoRuth Jessen Hickman, MD, a graduate of the Indiana University School of Medicine, is a medical and science writer in Bloomington, Ind.

 

References

  1. Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 2024.
  2. Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 2024.
  3. van den Bosch L, Luppi F, Ferrara G, Mura M. Immunomodulatory treatment of interstitial lung disease. Ther Adv Respir Dis. 2022;16:17534666221117002.

Adapted from an article in the August 2024 issue of The Rheumatologist (Vol. 18, No. 8).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceSjögren’s DiseaseSystemic Sclerosis Tagged with:Interstitial Lung Diseaseinterstitial lung disease (ILD)Sjögren’s Disease supplement

Related Articles
    Editor's Pick

    The ACR and CHEST Release 2 New ILD Guidelines

    July 9, 2024

    Clinicians should not rely on glucocorticoids as a first-line treatment of SARD-ILD in patients with systemic sclerosis, according to a strong recommendation in a new ILD treatment guideline from the ACR and CHEST. The guideline is one of two addressing the screening, monitoring and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs).

    What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

    December 1, 2012

    Patients with systemic sclerosis (SSc), poly-/dermatomyositis (PM/DM), or rheumatoid arthritis (RA) appear to carry the greatest risk for developing connective tissue disease-associated interstitial lung disease (CTD-ILD)
     

    Experts Discuss Guidelines for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease

    March 6, 2025

    Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Scleroderma Program, notes that more recent studies have increased our awareness…

    Considerations for Lung Transplants in Patients with SARD-ILD

    December 2, 2024

    At this ACR Convergence 2024 session, Sonye Danoff, MD, PhD, discussed many factors that need to be considered before referring patients with SARD-ILD for lung transplantation.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences